ArticleAnnals of surgical oncology2020
Role of Sentinel Lymph Node Biopsy in Microinvasive Breast Cancer.
Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Meta-analysis on axillary lymph node metastasis rate in ductal carcinoma in situ with microinvasion.Cancer medicine · 2024Pooled it
- Review
- Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node-Negative Microinvasive DCIS.The breast journal · 2026Article
- Utility of Surgical Axillary Staging in Microinvasive Ductal Carcinoma In Situ: A National Cancer Database Analysis.Annals of surgical oncology · 2025Article
- Update on the management of ductal carcinoma in situ of the breast: current approach and future perspectives.Japanese journal of clinical oncology · 2025Review
- Case Report: Mammary Paget's disease with multifocal microinvasive carcinoma and extensive lymph node metastasis: therapeutic challenges and insights from a case of stage pT1mic pN3c cM0.Frontiers in oncology · 2025Article
- New Insight for Axillary De-Escalation in Breast Cancer Surgery: "SoFT Study" Retrospective Analysis.Current oncology (Toronto, Ont.) · 2024Article
- Opportunities for De-Escalation of Axillary Surgery in Patients with Ductal Carcinoma in Situ with Microinvasion.Annals of surgical oncology · 2024Article
- Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience.Breast cancer research and treatment · 2024Article
- Prognostic Markers of Microinvasive Breast Carcinoma: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Microinvasive breast cancer and the role of sentinel lymph node biopsy.Scientific reports · 2022Article
- Low incidence of lymph node metastasis in patients with microinvasive breast cancer: a Korean nationwide study.Annals of surgical treatment and research · 2022Article
- Regional Lymph Node Metastasis and Axillary Surgery of Microinvasive Breast Cancer: A Population-Based Study.Diagnostics (Basel, Switzerland) · 2022Article
- Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review.The Journal of international medical research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroinvasive ductal carcinoma (DCISM), defined as DCIS with a focus of invasive carcinoma ≤ 1 mm, can be managed similarly to pure DCIS; however, management of the axilla in DCISM has been a subject of debate. Reports in the literature differ on the utility and necessity of sentinel lymph node biopsy (SLNB) for DCISM. The aim of the present study was to identify risk factors for nodal disease in patients with DCISM, which can help develop a selective approach to SLNB in this patient population.
methodsThe National Cancer Database was used to select patients with DCISM (pT1mi), diagnosed from 2012 to 2015, who underwent SLNB. Multivariable regression analysis was performed to determine associations between sentinel lymph node metastasis and relevant clinical variables.
resultsOur cohort comprised of 2609 patients with pT1mi who underwent SLNB. Of these, 76 (2.9%) were found to have sentinel lymph node metastases on final pathology. Low/intermediate grade tumors were associated with decreased SLN metastasis (OR 0.50, CI 0.28-0.92). Age and receptor status of the tumor did not have a clear association in predicting SLN metastases.
conclusionsThe rate of sentinel node metastases in DCISM is low at only 2.9% in this national study. Tumor grade was identified as influencing the risk of SLN metastases. This information can factor into shared decision-making for SLNB in patients with DCISM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.